Literature DB >> 19949822

Effect of mood stabilizers on gene expression in lymphoblastoid cells.

Hiroko Sugawara1, Kazuya Iwamoto, Miki Bundo, Mizuho Ishiwata, Junko Ueda, Chihiro Kakiuchi, Jun Ishigooka, Tadafumi Kato.   

Abstract

Lithium and valproate are widely used as effective mood stabilizers for the treatment of bipolar disorder. To elucidate the common molecular effect of these drugs on non-neuronal cells, we studied the gene expression changes induced by these drugs. Lymphoblastoid cell cultures derived from lymphocytes harvested from three healthy subjects were incubated in medium containing therapeutic concentrations of lithium (0.75 mM) or valproate (100 microg ml(-1)) for 7 days. Gene expression profiling was performed using an Affymetrix HGU95Av2 array containing approximately 12,000 probe sets. We identified 44 and 416 genes that were regulated by lithium and valproate, respectively. Most of the genes were not commonly affected by the two drugs. Among the 18 genes commonly altered by both drugs, vascular endothelial growth factor A (VEGFA), which is one of the VEGF gene isoforms, showed the largest downregulation. Our findings indicate that these two structurally dissimilar mood stabilizers, lithium, and valproate, alter VEGFA expression. VEGFA might be a useful biomarker of their effects on peripheral tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949822     DOI: 10.1007/s00702-009-0340-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  68 in total

1.  Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax.

Authors:  T C Somervaille; D C Linch; A Khwaja
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

2.  The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3.

Authors:  G Chen; L D Huang; Y M Jiang; H K Manji
Journal:  J Neurochem       Date:  1999-03       Impact factor: 5.372

3.  Mood stabilizing drugs expand the neural stem cell pool in the adult brain through activation of notch signaling.

Authors:  Mikito Higashi; Noriko Maruta; Alan Bernstein; Kazuhiro Ikenaka; Seiji Hitoshi
Journal:  Stem Cells       Date:  2008-05-08       Impact factor: 6.277

4.  The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS.

Authors:  G Chen; W Z Zeng; P X Yuan; L D Huang; Y M Jiang; Z H Zhao; H K Manji
Journal:  J Neurochem       Date:  1999-02       Impact factor: 5.372

5.  Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate.

Authors:  J Cui; L Shao; L T Young; J-F Wang
Journal:  Neuroscience       Date:  2006-12-19       Impact factor: 3.590

6.  Enhancement of hippocampal neurogenesis by lithium.

Authors:  G Chen; G Rajkowska; F Du; N Seraji-Bozorgzad; H K Manji
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

7.  BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore.

Authors:  C Vande Velde; J Cizeau; D Dubik; J Alimonti; T Brown; S Israels; R Hakem; A H Greenberg
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells.

Authors:  M Michaelis; T Suhan; U R Michaelis; K Beek; F Rothweiler; L Tausch; O Werz; D Eikel; M Zörnig; H Nau; I Fleming; H W Doerr; J Cinatl
Journal:  Cell Death Differ       Date:  2006-03       Impact factor: 15.828

Review 9.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

Authors:  Napoleone Ferrara
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

10.  Fibroblast and lymphoblast gene expression profiles in schizophrenia: are non-neural cells informative?

Authors:  Nicholas A Matigian; Richard D McCurdy; François Féron; Christopher Perry; Heather Smith; Cheryl Filippich; Duncan McLean; John McGrath; Alan Mackay-Sim; Bryan Mowry; Nicholas K Hayward
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

View more
  15 in total

Review 1.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

2.  Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines.

Authors:  M S Breen; C H White; T Shekhtman; K Lin; D Looney; C H Woelk; J R Kelsoe
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

3.  Mood-stabilizers differentially affect housekeeping gene expression in human cells.

Authors:  Timothy R Powell; Georgia Powell-Smith; Kate Haddley; Peter Mcguffin; John Quinn; Leonard C Schalkwyk; Anne E Farmer; Ursula M D'Souza
Journal:  Int J Methods Psychiatr Res       Date:  2014-02-12       Impact factor: 4.035

4.  Distinct lithium-induced gene expression effects in lymphoblastoid cell lines from patients with bipolar disorder.

Authors:  Gabriel R Fries; Gabriela D Colpo; Nancy Monroy-Jaramillo; Junfei Zhao; Zhongming Zhao; Jodi G Arnold; Charles L Bowden; Consuelo Walss-Bass
Journal:  Eur Neuropsychopharmacol       Date:  2017-09-20       Impact factor: 4.600

5.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

6.  Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling.

Authors:  A Gupta; T G Schulze; V Nagarajan; N Akula; W Corona; X-y Jiang; N Hunter; F J McMahon; S D Detera-Wadleigh
Journal:  Pharmacogenomics J       Date:  2011-03-08       Impact factor: 3.550

7.  A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder.

Authors:  Richard C McEachin; Haiming Chen; Maureen A Sartor; Scott F Saccone; Benjamin J Keller; Alan R Prossin; James D Cavalcoli; Melvin G McInnis
Journal:  BMC Syst Biol       Date:  2010-11-19

8.  Novel integrative genomic tool for interrogating lithium response in bipolar disorder.

Authors:  J G Hunsberger; F L Chibane; A G Elkahloun; R Henderson; R Singh; J Lawson; C Cruceanu; V Nagarajan; G Turecki; A Squassina; C D Medeiros; M Del Zompo; G A Rouleau; M Alda; D-M Chuang
Journal:  Transl Psychiatry       Date:  2015-02-03       Impact factor: 6.222

9.  Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders.

Authors:  Breno Satler Diniz; Rodrigo Machado-Vieira; Orestes Vicente Forlenza
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-12       Impact factor: 2.570

10.  Convergent functional genomic studies of ω-3 fatty acids in stress reactivity, bipolar disorder and alcoholism.

Authors:  H Le-Niculescu; N J Case; L Hulvershorn; S D Patel; D Bowker; J Gupta; R Bell; H J Edenberg; M T Tsuang; R Kuczenski; M A Geyer; Z A Rodd; A B Niculescu
Journal:  Transl Psychiatry       Date:  2011-04-26       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.